DEUTSCHE BANK AG\ - CTI BIOPHARMA CORP ownership

CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 44 filers reported holding CTI BIOPHARMA CORP in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
DEUTSCHE BANK AG\ ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q1 2023$259,808
+0.2%
61,859
+43.3%
0.00%
Q4 2022$259,361
+5.0%
43,155
+1.6%
0.00%
Q3 2022$247,000
-6.4%
42,493
-4.2%
0.00%
Q2 2022$264,00044,345
+738983.3%
0.00%
Q1 2022$0
-100.0%
6
-100.0%
0.00%
-100.0%
Q4 2021$2,407,000
-15.9%
970,4350.0%0.00%0.0%
Q3 2021$2,863,000
+18.0%
970,4350.0%0.00%0.0%
Q2 2021$2,426,000970,435
+16173816.7%
0.00%
Q1 2021$060.0%0.00%
Q4 2020$060.0%0.00%
Q3 2020$060.0%0.00%
Q2 2020$0
-100.0%
6
-100.0%
0.00%
Q2 2019$58,000
-47.3%
69,735
-39.2%
0.00%
Q1 2019$110,000
-59.1%
114,632
-68.8%
0.00%
Q4 2018$269,000
-48.6%
367,717
+51.5%
0.00%
Q3 2018$523,000
-41.4%
242,755
+35.3%
0.00%
Q2 2018$892,000
+424.7%
179,465
+182.1%
0.00%
Q4 2017$170,000
-74.0%
63,621
-69.0%
0.00%
Q3 2017$654,000205,099
+70623.8%
0.00%
Q2 2017$0290
+1511.1%
0.00%
Q1 2017$0180.00%
Other shareholders
CTI BIOPHARMA CORP shareholders Q3 2019
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 4,068,191$4,719,0009.14%
CAXTON CORP 619,460$719,0000.76%
BVF INC/IL 6,929,690$8,038,0000.50%
NEA Management Company, LLC 7,140,450$8,283,0000.33%
Orbimed Advisors 9,520,600$11,044,0000.16%
Renaissance Technologies 2,103,792$2,440,0000.00%
Paloma Partners Management Co 30,289$35,0000.00%
WEDBUSH SECURITIES INC 12,600$15,0000.00%
HRT FINANCIAL LP 19,710$22,0000.00%
FIRST MANHATTAN CO. LLC. 33$00.00%
View complete list of CTI BIOPHARMA CORP shareholders